home > news > detailed info

WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research

WCG Clinical

PRINCETON, N.J. & OVERLAND PARK, Kan. — WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research’s (DVCR) industry-leading, green-designed research complex in Overland Park, Kansas — who selected WCG as their institutional review board (IRB) of record — these expanded services will provide faster timelines in the clinical trial process without sacrificing superior levels of human subject protection for early stage and clinical pharmacology research.

“This expansion enables early phase research to complete in more predictable fashion and ensures participant protection through every stage of the study,” said Mark McDonald, president of WCG IRB. “Based on the high propensity for changes in first in human research, sponsors are adding cohorts and doses to study designs which often increases the need for additional amendments to the study protocol, ultimately contributing to the frequency of delays. Implementing customized operational teams that focus on providing efficient, high-quality processing services, speeding up the operations while maintaining focus on thorough board reviews, allows WCG IRB to fundamentally change the way Phase I research is executed.”

With the introduction of this new model, clients will:
  • Benefit from dedicated operations to support accelerated processing of submissions in preparation for IRB review
  • Continue to recognize the benefits from WCG’s over 50 years of unparalleled expertise Have a single point of contact who will be available to address questions and help clients navigate the IRB process
  • Receive timely review of IRB submission materials with a board that convenes daily and delivers predictable turnaround times for all study items

With more than 20 years of experience in the clinical research industry, Dr. Brad Vince, CEO and medical director of DVCR, has served as an investigator in over 600 clinical trials and authored numerous scientific publications.

“It’s our vision to create one of the most innovative and technologically advanced Phase I units in the world,” said Dr. Vince. “The ability to accelerate study timelines while maintaining the highest degree of study volunteer safety was the key factor in selecting WCG IRB, the largest and most trusted central IRB in the U.S., for our early phase clinical trials.”
phone 609.945.0101
email 212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA
Print this page
Send to a friend
News and Press Releases


Effective January 1, 2023, Bekki Brown will assume the role of President & Chief Executive Officer of UBC
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach


Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement